Dymon Asia Capital (Singapore)’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Dymon Asia Capital (Singapore)'s VRTX Position: Q2 2026 in Review
Dymon Asia Capital (Singapore) opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 5,546 shares worth $2.75M. The stake represents 0.12% of the portfolio and ranks #102 among its holdings. This is a return to the name: Dymon Asia Capital (Singapore) previously reported a position in VRTX as recently as Q4 2025.
Dymon Asia Capital (Singapore) first reported a position in VRTX in Q4 2020 and has held it in 3 quarters since. 882 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Dymon Asia Capital (Singapore) held 5,546 shares of Vertex Pharmaceuticals worth $2.75M as of Q2 2026.
- Vertex Pharmaceuticals was a new Dymon Asia Capital (Singapore) position in Q2 2026.
- Vertex Pharmaceuticals made up 0.12% of Dymon Asia Capital (Singapore)'s portfolio in Q2 2026, its #102 holding.
- Dymon Asia Capital (Singapore) first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
- 882 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Dymon Asia Capital (Singapore)'s 13F filing for Q2 2026, filed 23 Jul 2026.